We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Discovery May Help Doctors Treat Infertility

By Biotechdaily staff writers
Posted on 29 Aug 2005
A new study shows that fertility drugs may be ineffective for women who lack a gene called the estrogen receptor beta, suggesting that women who lack this receptor may need alternative infertility treatments. More...
This discovery was reported in the August 2005 issue of Endocrinology.

The estrogen receptor beta is one of two estrogen proteins that mediate the effects of estrogen hormones and are present throughout female reproductive tissue. In mice that were genetically engineered to lack the estrogen receptor beta, fertility drugs did not improve ovulation rates, indicating that this receptor plays a critical role in ovulation.

"What we found is that the beta estrogen receptor plays a role in moving the egg outside the ovary so it can be fertilized,” said Kenneth Korach, Ph.D., laboratory chief at the U.S. National Institute of Environmental Health Sciences (NIEHS, Bethesda, MD, USA), where the research took place. "We never knew before what function this receptor played in reproduction.”

If the results from this animal study are found to be applicable to humans, a simple blood test will be able to provide enough information to determine if a genetic mutation may be altering the function of the estrogen receptor beta. Coupled with other information from medical tests, this test will also help diagnose infertility and help determine treatment options.

It was generally thought that there was only one receptor, the alpha receptor, that responded to estrogen. It was not until 1996 that the estrogen receptor beta was discovered. According to the current study, the beta receptor plays a more significant role in ovarian function than the alpha receptor.

The beta receptor is also known to respond to environmental and dietary chemicals that can mimic the effects of estrogen and stimulate the body's natural hormones. One example of this is genistein, a component of soy products. The new findings suggest that such environmental exposures could interact with estrogen receptor beta and possibly alter ovarian function. An earlier NIEHS study used an in vitro approach to reveal the role that estrogen receptors play in ovulation.

"The tools and animal models necessary to do these types of studies have only recently become available, but are already helping us to better understand the role of estrogen in the ovary,” stated lead author John Couse, Ph.D.




Related Links:
National Institute of Environmental Health Sciences

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.